Pacad Investment Ltd. purchased a new stake in Juno Therapeutics, Inc. (NASDAQ:JUNO) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 3,500 shares of the biopharmaceutical company’s stock, valued at approximately $105,000.

A number of other hedge funds also recently bought and sold shares of JUNO. Teachers Advisors LLC raised its position in Juno Therapeutics by 12.3% in the 4th quarter. Teachers Advisors LLC now owns 60,834 shares of the biopharmaceutical company’s stock valued at $1,147,000 after purchasing an additional 6,643 shares in the last quarter. Nisa Investment Advisors LLC acquired a new stake in Juno Therapeutics in the 1st quarter valued at about $200,000. Wells Fargo & Company MN raised its position in Juno Therapeutics by 238.4% in the 1st quarter. Wells Fargo & Company MN now owns 121,392 shares of the biopharmaceutical company’s stock valued at $2,693,000 after purchasing an additional 85,516 shares in the last quarter. Canada Pension Plan Investment Board raised its position in Juno Therapeutics by 111.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 94,400 shares of the biopharmaceutical company’s stock valued at $2,095,000 after purchasing an additional 49,700 shares in the last quarter. Finally, Great West Life Assurance Co. Can raised its position in Juno Therapeutics by 80.5% in the 1st quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 3,800 shares in the last quarter. 70.76% of the stock is currently owned by institutional investors.

Shares of Juno Therapeutics, Inc. (JUNO) opened at 44.30 on Monday. The stock’s market cap is $4.65 billion. The stock has a 50 day moving average price of $34.04 and a 200-day moving average price of $27.13. Juno Therapeutics, Inc. has a 12 month low of $17.52 and a 12 month high of $47.00.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.24). The company had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. Juno Therapeutics’s revenue was down 22.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.64) EPS. On average, analysts forecast that Juno Therapeutics, Inc. will post ($3.12) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Pacad Investment Ltd. Purchases New Stake in Juno Therapeutics, Inc. (JUNO)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/18/pacad-investment-ltd-purchases-new-stake-in-juno-therapeutics-inc-juno.html.

A number of equities research analysts have issued reports on the company. ValuEngine raised Juno Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. Wells Fargo & Company reiterated an “outperform” rating and issued a $54.00 price objective (up previously from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Barclays PLC began coverage on Juno Therapeutics in a research note on Wednesday, September 6th. They set an “overweight” rating and a $55.00 price target on the stock. Standpoint Research restated a “reduce” rating on shares of Juno Therapeutics in a research note on Thursday, August 31st. Finally, Raymond James Financial, Inc. upgraded Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price target on the stock in a research note on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company’s stock. Juno Therapeutics has an average rating of “Hold” and a consensus price target of $34.88.

In other news, EVP Robert Azelby sold 12,850 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $44.95, for a total value of $577,607.50. Following the completion of the sale, the executive vice president now owns 37,439 shares in the company, valued at $1,682,883.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Steve Harr sold 8,750 shares of the stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total value of $262,500.00. Following the completion of the sale, the chief financial officer now owns 736,189 shares of the company’s stock, valued at approximately $22,085,670. The disclosure for this sale can be found here. Insiders sold 8,119,219 shares of company stock valued at $220,455,844 in the last 90 days. Corporate insiders own 15.26% of the company’s stock.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.